Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...

Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its ...

Merck & Co. Inc. closed $36.29 below its 52-week high ($134.63), which the company achieved on June 25th.

The FDA accepts MRK's BLA for clesrovimab, its monoclonal antibody, to protect infants from RSV disease. A decision from the ...

Merck & Co. is doubling down on getting into the white-hot weight-loss drug market, scooping up a pill developed in China. Merck said Wednesday it will pay Hansoh Pharma $112 million upfront for the ...

Merck has become inexpensive again and combines a good growth outlook with a nice and growing dividend. Learn why MRK stock ...

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from ...

(RTTNews) - Merck & Co., Inc. (MRK), Wednesday announced that the company has entered into an exclusive global license deal with China-based Hansoh Pharma to develop, manufacture and commercialize ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...